Strata Critical Medical, Inc. (SRTA) Stock Price & Analysis
Strata Critical Medical, Inc. (SRTA) fell 4.43% to USD 5.61 as of June 10, 2026 at 00:25 UTC, according to Nexqual real-time market data.
SRTA last closed at USD 5.87; the session ranged USD 5.4–5.97 on volume of 1,453,575 shares. Market capitalization is $485.41M, with a 52-week range of USD 3.57–6.5 (NCM). Source: Nexqual, June 10, 2026 at 00:25 UTC.
Key Statistics (as of June 10, 2026 at 00:25 UTC)
| Price | USD 5.61 |
|---|---|
| Change | ▼ 4.43% (down) |
| Previous Close | USD 5.87 |
| Open | USD 5.9 |
| Day Range | USD 5.4 – 5.97 |
| 52-Week Range | USD 3.57 – 6.5 |
| Volume | 1,453,575 shares |
| Market Cap | $485.41M |
| Exchange | NCM |
Technical Analysis (SRTA)
Nexqual's technical model rates SRTA "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:25 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.62 (neutral) |
| vs SMA50 | Above (USD 5.13) |
| MACD | 0.22 (positive) |
Analyst Ratings (SRTA)
Wall Street analysts rate SRTA "Strong Buy" based on 4 analysts, with a mean price target of USD 9.25 (range USD 8–11.5), per Nexqual as of June 10, 2026 at 00:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 9.25 |
| High Target | USD 11.5 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SRTA)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $67.19M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.04 vs est -0.04 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.01 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.02 ▼ miss |
| 2025-06-30 | USD -0.04 vs est -0.05 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financials & Fundamentals (SRTA)
| Total Revenue | $228.58M |
|---|---|
| Revenue Growth (YoY) | +87.40% |
| Gross Margin | +21.08% |
| Operating Margin | -2.83% |
| Profit Margin | +20.56% |
| ROE | -6.35% |
| Debt / Equity | 1.56 |
| Current Ratio | 5.93 |
| Total Cash | $58.79M |
| Total Debt | $4.47M |
| Free Cash Flow | $-24.45M |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financial Health Score (SRTA)
Nexqual rates Strata Critical Medical, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:25 UTC.
| Growth | Critical — Revenue -21% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 21%, operating -3% |
| Balance Sheet | Strong — $59M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$24M, burning cash |
| Efficiency | Critical — ROE -6%, ROA -1.9% |
Ownership (SRTA)
| Insider Ownership | +13.88% |
|---|---|
| Institutional Ownership | +78.92% |
| Shares Outstanding | 86.53M |
| Float | 61.82M |
| Short % of Float | +10.14% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Leadership (SRTA)
Strata Critical Medical, Inc. is led by Melissa M. Tomkiel (age 44), Co- CEO, General Counsel, Corporate Secretary & Director, per Nexqual as of June 10, 2026 at 00:25 UTC.
| Co- CEO, General Counsel, Corporate Secretary & Director | Melissa M. Tomkiel (age 44) |
|---|---|
| Co-CEO, CFO & Director | William A. Heyburn (age 36) |
| CFO of Clinical Services & VP of Finance and Investor Relations | Mathew Schneider C.F.A. |
Major Backers & Investors (SRTA)
Notable institutional backers of Strata Critical Medical, Inc. include ARK Invest, Third Point, LLC, First Eagle Investment Management, LLC, according to Nexqual as of June 10, 2026 at 00:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 16.43% |
| Third Point, LLC | 5.78% |
| First Eagle Investment Management, LLC | 4.8% |
| Northern Right Capital Management, L.P. | 4.73% |
| AWM Investment Company, Inc. | 3.26% |
| Royce & Associates LP | 3.25% |
| Pillsbury Lake Capital LLC | 3.01% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.85% |
| Vanguard Group | 6.57% |
| Geode Capital | 1.96% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
From Strata Critical Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Technology We also utilize proprietary technology to manage staffing, training and chain of custody, as well as help customers streamline organ evaluation (through our Trinity Organ Placement Services - TOPS), procurement and logistics.
- We compete primarily based on our technology-enabled service and access to a wide variety of aircraft types, including jets, turboprops and helicopters, in many locations across the United States.
- Many of our transplant customers utilize services in both our Logistics and Clinical segments together given the ease of use inherent in our integrated offering, but this is not required.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EVTL | Vertical Aerospace Ltd. | USD 2.09 | ▼ 3.24% |
| UP | Wheels Up Experience Inc. | USD 7.2 | ▲ 0% |
| EVEX | Eve Holding, Inc. | USD 2.64 | ▼ 7.69% |
| JOBY | Joby Aviation, Inc. | USD 9.27 | ▼ 2.93% |
| QSI | Quantum-Si Incorporated | USD 0.99 | ▼ 6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:25 UTC. This page is informational and not investment advice.